HIM-1 Rev protein directs nuclear export of pre-mRNAs and mRNAs containing its binding site, the Rev response element (RRE). To define how Rev acts, we used conjugates between bovine serum albumin (BSA) and peptides comprising the Rev activation domain (BSA-R). BSA-R inhibited Rev-mediated nuclear RNA export, whereas a mutant activation domain peptide conjugate did not. BSA-R did not affect the export of mRNA, tRNA, or ribosomal subunits, but did inhibit export of 5S rRNA and spliceosomal U snRNAs. BSA-R was itself exported from the nucleus in an active, saturable manner. Thus, the Rev activation domain constitutes a nuclear export signal that redirects RREcontaining viral RNAs to a non-mRNA export pathway.
Introduction
Cellular RNA species as diverse as messenger RNA (mRNA), transfer RNA (tRNA), ribosomal RNA (rRNA), and spliceosomal small nuclear RNAs (snRNAs) are exported from the nucleus to the cytoplasm by an active, factor-mediated process. Although all molecules exit the nucleus via the nuclear pore complex, evidence has been provided that different factors mediate the export of specific RNA classes (reviewed by . Since most, if not all, RNAs associate with proteins in the cell nucleus, it is believed that RNA export is probably mediated by specific proteins that harbor appropriate export signals. For example, the export of 5S rRNA from the Xenopus laevis oocyte nucleus is inhibited when the RNA is mutated so that it can interact with neither transcription factor TFIIIA nor ribosomal protein L5 (Guddat et al., 1990) . Similarily, heterogenous nuclear ribonucleoproteins (hnRNPs) such as A1 might be involved in the export of mRNAs since PiSoI-Roma and Dreyfuss (1991, 1992) have shown that they shuttle constantly between the nuclear and cytoplasmic compartments. Factors that bind to the mTG cap structure are important for the export of the U1, U2, U4, and U5 spliceosomal snRNAs (Jarmo-:l:Present address: Department of Biochemistry, Katholieke Universiteit Nijmegen, 6500 HB Nijmegen, The Netherlands. Iowski et al., 1994) . A nuclear mTG cap-binding complex that is involved in the export of these RNAs has been characterized (Hamm and Mattaj, 1990; Izaurralde et al., 1992 Izaurralde et al., , 1994  reviewed by . So far, however, there is no clear indication of how these proteins might mediate nuclear export.
Export of RNAs has to be integrated with their processing. In the case of cellular pre-mRNAs, removal of introns by splicing is a prerequisite for export, and binding of spliceosomal factors actively retains pre-mRNA in the nucleus. Only after splicing is completed is the mature mRNA exported (Legrain and Rosbash, 1989) . In contrast, complex retroviruses such as human immunodeficiency virus type 1 (HIV-1) require the export of not only fully spliced mRNA but also unspliced and partially spliced viral mRNA (reviewed by Cullen, 1992) . Early in the HIV-1 replication cycle, only fully spliced viral mRNA coding for the regulatory proteins Tat, Rev, and Nef accumulates in the cytoplasm. Later in infection, the incompletely spliced and unspliced late viral mRNAs also enter the cytoplasm. This temporal coordination of viral mRNA nuclear export is facilitated by the RNA-binding Rev protein and its binding site, the Rev response element (RRE) (Feinberg et al., 1986; Emerman et al., 1989; Felber et al., 1989; Malim et al., 1989a; Chang and Sharp, 1989) . The RRE is present in all unspliced and partially spliced HIV-1 mRNA species but is eliminated from fully spliced viral mRNAs.
Rev has at least two distinct functions. The amino-terminal domain has been shown to be necessary and sufficient for RRE binding, Rev multimerization, and nuclear translocation (Malim et al., 1989a; Berger et al., 1991) . A second domain, termed the activation or effector domain, is believed to interact with one or more cellular factors required for Rev function since missense mutations in this region result in a trans-dominant negative phenotype (Malim et al., 1989b Mermer et al., 1990; Venkatesh and Chinnadurai, 1990) .
Other complex retroviruses, such as human T cell lymphopathic virus type I (HTLV-I) or equine infectious anemia virus, encode functionally equivalent proteins that are required for the production in the cytoplasm of u nspliced viral RNA. The best characterized is the HTLV-I Rex protein (reviewed by Cullen, 1992) . Simpler retroviruses, like Mason-Pfizer monkey virus, appear to use cellular proteins to achieve the same functional end (Bray et al., 1994) .
Two main models for Rev function have been proposed. One is that Rev may inhibit splicing or interfere with the assembly of the spliceosome. This hypothesis would imply that inhibiting spliceosome assembly would release premRNA for transport to the cytoplasm. Evidence in support of this idea has been provided (Chang and Sharp, 1989; Kjems et al., 1991; Kjems and Sharp, 1993; Stutz and Rosbash, 1994) . Alternatively, Rev might directly target viral pre-mRNA to the cytoplasm (Emerman et al., 1989; Felber et al., 1989; Malim et al., 1989a Malim et al., , 1989b Malim and Cullen, 1993; Fischer et al., 1994a) . Consistent with this view, Rev does not change the ratio between unspliced and spliced viral RNA in transfected cells but rather induces a pattern of cytoplasmic viral RNA that mirrors the pattern seen in cell nuclei in the absence of Rev (Malim et al., 1989a (Malim et al., , 1989b Malim and Cullen, 1993) . Additionally, Rev was able directly to promote nuclear export of RRE-containing mRNAs after nuclear injection into Xenopus oocytes independently of the presence of introns in these RNAs and thus presumably in the absence of spliceosome formation (Fischer et al., 1994a) .
The evidence summarized above suggested that a cellular factor facilitates the export of unspliced viral mRNA by interacting with the activation domain of Rev. We have tested this model and show here that bovine serum albumin (BSA) conjugates containing the Rev activation domain in the form of peptides are capable of inhibiting Revmediated export of RRE-containing RNAs, implying that this domain interacts with a cellular factor that is a component of a nuclear export system. Moreover, peptides derived from the activation domain are sufficient to induce the nuclear export of BSA via an active and saturable pathway, defining the activation domain as a nuclear export signal (NES). Further competition studies suggest that Rev allows RRE-containing RNAs to enter an export pathway that is distinct from that used by cellular mRNAs.
Results

Specific Saturation of Rev-Mediated RNA Export by a Peptide Comprising the Rev Activation Domain
To analyze whether Rev interacts with an essential limiting factor while exporting RRE-containing RNA, we searched for a specific competitor of Rev function. In analogy to experiments carried out with nuclear localization signal peptides (Goldfarb et al., 1986) , we cross-linked a peptide consisting of the activation domain of the Rev protein to BSA (BSA-R, peptides CLPPLERLTL)( Figure 1A ). Each molecule of BSA-R carried roughly 20 peptides (data not shown). To test whether a putative Rev-interacting factor would be titrated by BSA-R, we studied the Rev-mediated export of an RRE-containing RNA (pAd46 RNA; Fischer et al., 1994a) in the absence or presence of BSA-R. In the absence of Rev, pAd46 RNA is only slowly exported to the cytoplasm (Fischer et al., 1994a) . When coinjected into oocyte nuclei with Rev protein, a2P-labeled pAd46 RNA was mostly exported within 60 min ( Figure 1B , lanes 1 and 2). In contrast, in the presence of 10 I~g/p.I coinjected BSA-R, almost 90% of the injected pad46 RNA was still in the nucleus after 60 rain (compare lanes 1 and 2 with lanes 3 and 4 in Figure 1B ). The export inhibition by BSA-R is time and concentration dependent, as shown by releasing inhibition after a longer incubation or by varying the concentration of the BSA-R competitor ( Figure 1B , lanes 3-6; data not shown). The BSA-R competitor does not interfere with the binding of Rev to the RRE in vitro (data not shown).
Next, a peptide comprising the activation domain of the inactive Rev mutant M10 (Malim et al., 1989b) show an experiment in which BSA-R was injected at a concentration of 1 mg/ml. The nuclear export of pAd46 RNA was analyzed 60 rain later, Oocytes were incubated at 20°C before being dissected into nuclear (N) and cytoplasmic (C) fractions. RNA from both compartments was extracted and separated on a denaturing polyacrylamide gel. The injected RNA was detected by autoradiography.
1A). BSA-M did not inhibit the export of pAd46 RNA ( Figure  1B , lanes 7 and 8), indicating that the observed export inhibition by BSA-R was specific and mirrored the function of the Rev activation domain. These data strongly suggest that the Rev activation domain interacts with a limiting cellular factor and that this interaction is necessary for its export activity. As a further control of specificity, we made use of peptides derived from the HTLV-I regulatory protein Rex. Rev and Rex appear to be functionally equivalent, although their primary sequences differ considerably (Rimsky et al., 1988) . In particular, previous studies have shown that the activation domains of Rex and Rev are interchangeable (Rimsky et al., 1988; Weichselbraun et al., 1992) .
BSA-Rex (peptides CMDALSAQLYSSLSLDSPPSPP) was prepared and coinjected with pAd46 RNA and Rev protein into the nucleus of oocytes. The BSA-Rex conjugate inhibited the nuclear export of pAd46 RNA with an efficiency similar to that of BSA-R (Figure 2 , lanes 9-12 and 13-16).
The Rev Activation Domain Is an NES
To obtain more insight into the mode of action of the BSA-R conjugate, we examined its localization. Rev has been shown to shuttle rapidly between the nucleus and the cyto- plasm. This depends on an intact activation domain and also on the separate nuclear localization signal of Rev. BSA-R or BSA-M was labeled with 12~1. The proteins were injected into the nuclei of oocytes, and their distribution between the nucleus and the cytoplasm was followed over a period of I hr ( Figure 3 ; note that the cross-linking procedure induces some protein oligomerization). While BSA-M (as well as BSA or BSA conjugated with the inverse activation domain peptide; data not shown; see also Mandell and Feldherr, 1990 ) remained entirely in the nucleus after 2 hr ( Figure 3A , lanes 3 and 4), BSA-R entered the cytoplasm at a rate similar to that exhibited by RRE-containing RNAs in the presence of Rev ( Figure 3A , lanes 1 and 2; Figure 3B , lanes 1-6). Nuclear export of BSA-R was, however, severely inhibited when the oocytes were incubated at 4°C ( Figure 3B , lanes 11 and 12). Thus, the Rev activation domain acts as an NES, able to direct the export of a protein to which it is attached to the cytoplasm in a temperature-dependent manner. The export of BSA-R was not affected by coinjecting a 40-fold excess of BSA-M competitor ( Figure 3A , lanes 7 and 8), but was strongly reduced by the same amount of BSA-R ( Figure 3A , lanes 5 and 6). The inhibition of BSA-R export by BSA-R competitor was concentration and time dependent ( Figure 3B , lanes 7-10; data not shown). Thus, export saturation by BSA-R is highly specific and dependent on the presence of an intact Rev activation domain.
The NES Also Mediates the Export of BSA in Human Somatic Cells
Since Rev normally exerts its RNA export-promoting function in HIV-l-infected human cells, we analyzed whether the Rev NES was also functionally active in human somatic cells. To test this, we labeled BSA-R and BSA-M conjugates with two different fluorescent dyes and injected them into HeLa cell nuclei. After a 1 hr incubation, localization was analyzed by fluorescence microscopy. BSA-R (stained green) was exported to the cytoplasm, while BSA-M (stained red) remained almost entirely in the nuclear compartment ( Figure 4A ). Therefore, BSA-R and BSA-M exhibited the same behavior in HeLa cells as in oocytes.
Export of BSA-R was again temperature dependent (Figure 4B) and specifically saturable by an excess of unla- Figure 3. The HIV-1 Activation Domain Peptide Targets BSA to the Cytoplasm (A) 12Sl-labeled BSA-R (lanes 1 and 2) or BSA-M (lanes 3 and 4) (0.25 mg/ml each) was injected into the nucleus of oocytes alone, or BSA-R was injected with either a 40-fold molar excess of unlabeled BSA-R (lanes 5 and 6) or BSA-M (lanes 7 and 8). Export was examined 2 hr later by protein extraction from nuclear (N) and cytoplasmic (C) fractions and by analysis on SDS-polyacrylamide gels.
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(B) Nuclear export of iodinated BSA-R was analyzed ir:nmediately after injection (lanes 1 and 2) or after 30 min (lanes 3 and 4) and 60 min (lanes 5 and 6). Lanes 7-10 show nuclear export after 60 min of iodinated BSA-R in the presence of a 40-fold (lanes 7 and 8) or 4-fold (lanes 9 and t0) molar excess of unlabeled BSA-R or at 4°C (lanes 11 and 12).
beled BSA-R ( Figure 4C ) but not BSA-M ( Figure 4D ). Interestingly, the nuclear BSA-R was found predominantly in the nucleoplasm. The nucleoli of these cells were devoid of label. The interaction between the NES and the cellular export factor is therefore not likely to occur in the nucleolus even though Rev appears to accumulate there.
Rev-Mediated Export and Cellular mRNA Export Require Different Limiting Factors
The above observations allowed a comparison of Revmediated RNA export and cellular mRNA export pathways. A possible mode of Rev action is to overcome the retention in the nucleus caused by the presence of a spliceosome on a pre-mRNA, thereby facilitating access of the pre-mRNA to the cellular mRNA export pathway. If this were the case, the saturation of the Rev-mediated export pathway by injection of BSA-R would also be expected to inhibit mRNA export. To test this, we analyzed in X. laevis oocytes the export of the pAd48 pre-mRNA and the products derived from it by splicing, pAd48 is a truncated adenovirus 2 major late transcription unit that consists of the first (L1) and second (L2) leader exons and a portion of intron 1 into which the RRE has been inserted (Fischer et al., 1994a) . pAd48 pre-mRNA is efficiently spliced in oocytes. Because the pre-mRNA and the excised intron lariat contain the RRE, they are efficiently exported upon binding to Rev. They are, however, like cellular pre-mRNAs and excised introns, retained in the nucleus in the absence of Rev. The spliced mRNA product does not contain an RRE and is exported independently of the presence of Rev (Fischer et al., 1994a) . In vitro transcribed pAd48 pre-mRNA was injected into the nucleus of oocytes along with Rev protein and either BSA-R or, as a control, BSA-M. Export and splicing were then analyzed 1, 3, and 6 hr later. The injection of the BSA-M peptide had no effect on the kinetics of Revmediated export of RRE-containing RNA species ( Figure  5A ; see also Figure 1B ). However, coinjection of BSA-R strongly inhibited the export of the excised RRE-containing intron lariat ( Figure 5A ). In contrast, the export rate of the spliced mRNA product was not affected by the presence of BSA-R competitor ( Figure 5A ). Because the mRNA does not contain the RRE, it is presumably exported to the cytoplasm by means of the mRNA export pathway. The inhibition of export by BSA-R is therefore specific for the RRE-containing RNAs whose export is mediated by Rev, in this case the pre-mRNA and the intron lariat.
To clarify whether the inability of BSA-R to inhibit cellular mRNA export was a general phenomenon, we examined the transport of an mRNA without introns, namely the mRNA coding for dihydrofolate reductase, DHFR (JarmoIowski et al., 1994) . As a control, we coinjected RREcontaining pAd46 RNA. In the absence of Rev, pAd46 RNA is exported like an mRNA, but its export rate can be greatly stimulated by Rev (Fischer et al., 1994a) . Initially, 32P-labeled DHFR and pAd46 RNAs were injected into the nucleus of oocyt es along with Rev, and their nuclear export was analyzed 1 hr and 4 hr later ( Figure 5B ). Both DHFR and pAd46 RNAs were largely exported to the cytoplasm within 4 hr ( Figure 5B, lanes 1-4) . When BSA-R was coinjected, the export of pAd46 mRNA was efficiently inhibited in a concentration-and time-dependent manner ( Figure  5B , lanes 5-8; data not shown). In contrast, there was no difference in the export kinetics of the DHFR mRNA after coinjection with either BSA-R or BSA-M ( Figure 5B , lanes 5-12).
These data strongly suggest that the cofactor required for Rev-dependent RNA export is not required for the export of cellular mRNA to the cytoplasm. We next asked whether limiting factors required for the export of cellular mRNA were also required for Rev-mediated export. To analyze this possibility, we tested whether saturation of the mRNA export pathway by injection of an excess of mRNA competitor had any effect on the kinetics of Revmediated export. For this experiment, two 32P-labeled mRNAs without introns, DHFR RNA and pAd46 RNA, were coinjected. Both were exported in the absence of Rev. However, pAd46 RNA is unstable in the cytoplasm, and after 2 hr, much of the exported pAd46 RNA was degraded ( Figure 6, lanes 1-4) . The export of both 32P-labeled DHFR and pAd46 RNAs were efficiently inhibited in the presence of an excess of unlabeled DHFR mRNA competitor. In this case, the pAd46 RNA remained in the nucleus and was stable ( Figure 6, lanes 5-8) . Thus, in the absence of Rev, both RNAs were exported to the cytoplasm by means of the mRNA export pathway. Next, DHFR and pAd46 RNAs were injected into the nucleus with a 10-fold molar excess of Rev protein. Again, injections were carried out either with or without an excess of unlabeled competitor mRNA. Both RNAs were transported to the cytoplasm in the ab- sence of competitor with comparable export kinetics. The export of DHFR mRNA was unaffected by the presence of Rev, while the pAd46 RNA export rate was enhanced (compare lanes 1-4 with lanes 9-12 in Figure 6 ). In the presence of the competitor mRNA, the export of 32p. labeled DHFR mRNA was efficiently inhibited, showing that the mRNA export pathway was saturated ( Figure 6 , lanes 13-16). Under the same conditions, however, Revmediated export of pAd46 RNA was only slightly affected ( Figure 6, lanes 13-16) . In other experiments, mRNA competitor had no effect on the Rev-mediated export of pAd46, and it is possible that the effect observed in this case may be the result of a small fraction of pAd46 RNA not being In experiments shown in lanes 5-8 and 13-16, 0.4 pmol of unlabeled DHFR mRNA competitor was also coinjected. Oocytes were analyzed as described in Figure 1 . Abbreviations: N, nuclear; C, cytoplasmic.
saturated with Rev and therefore leaving the nucleus by the mRNA export pathway. Because the saturation of the mRNA export pathway did not affect Rev-dependent RNA export and vice versa, both pathways require different limiting factors and are therefore mechanistically different.
BSA-R Inhibits the Nuclear Export of 5S rRNA and Spliceosomal snRNAs
We next asked whether factors required for the export of other cellular RNAs were affected by Rev. Specific export factors have been shown to be required for the export of spliceosomal snRNAs, 5S rRNA, tRNA, and rRNAs in the form of ribosomal subunits (Zasloff, 1983; Khanna-Gupta and Ware, 1989; Bataille et al., 1990; Jarmolowski et al., 1994) . 32P-labeled tRNA s+', U1ASm, 5S rRNA, and (as a control) DHFR mRNA were injected into the nucleus of oocytes, and export was studied either in the presence or absence of an excess of BSA-R or BSA-M competitor. The U I~S m mutant RNA was chosen to study snRNA export since this RNA is exported as efficiently as wild-type U1 RNA but is unable to reenter the nucleus as a result of the absence of an Sm site (Harem and Mattaj, 1990; Jar.-molowski et al., 1994) . In the absence of competitor ( Figure 7A , lanes 1-4), U1ASm and DHFR mRNA were almost quantitatively exported within 4 hr, and approximately 50% of each was exported after 2 hr. Export of tRNA was much faster: after 1 hr, transport was complete, and after 30 rain, more than 60% of the tRNA had left the nucleus. Export of 5S rRNA was slower, and the absolute rate depended greatly on the batch of oocytes used. In most cases, approximately 70% of the injected 5S rRNA was exported within 4 hr, -8) , or BSA-R (lanes 9-12) at concentrations of 10 mg/ml. The nuclear export of DHFR mRNA, U1ASm, and 5S rRNA was analyzed after 2 and 4 hr; the nuclear export of tRNA was analyzed after 30 min and 1 hr. Analysis of RNA was carried out as described in the legend to Figure 1 . Even higher amounts of BSA-R competitor (up to 30 mg/ml was tested) showed identical results. Abbreviations: N, nuclear; C, cytoplasmic. (B) 3~P-labeled ribosomes purified from cultured HeLa cells were injected into the nucleus of oocytes (5 ng of ribosomes per oocyte) either without competitor or with 10 mg/mi BSA-R or BSA-M competitor. Export was analyzed after 90 and 180 min by quantitation of autoradiographs containing the radiolabeled 28S and 18S rRNA after separation on a denaturing gel. Average values for each timepoint are shown. Percent transport indicates the amount of stable rRNA that was exported at the indicated timepoint.
whereas after 2 hr, only about 20% was found in the cytoplasm ( Figure 7A, lanes 1-4) . When the same RNAs were injected along with an excess of either BSA-R competitor or BSA-M control conjugates, the export kinetics of DHFR was unaffected, which confirmed the data described above ( Figure 7A, lanes 5-12) . Similarly, the export of tRNA was not specifically affected by the BSA-R competitor. In contrast, the export of both 5S rRNA and U1ASm RNA was almost entirely inhibited by BSA-R coinjection even after 4 hr incubation (compare lanes 1-8 with lanes 9-12 in Figure 7A ). In additional experiments, we observed that the export of not only U1ASm but also of all other spliceosomal m~G-capped snRNAs was strongly inhibited by BSA-R (data not shown).
To test whether the export of ribosomal subunits was affected when Rev-mediated export was saturated, we injected 32P-labeled ribosomes isolated from HeLa cells into the nucleus of oocytes either without competitor or along with BSA-R or BSA-M ( Figure 7B ). Neither BSA-R nor BSA-M had any specific effect on the export kinetics of ribosomes ( Figure 7B ), suggesting that, like cellular mRNAs and tRNAs, ribosomal subunits do not leave the nucleus via the pathway that can be saturated by injection of BSA-R.
Discussion
tn this work we have investigated the mechanism of HIV-1 Rev-mediated RNA export. Using an approach similar to that which led to the identification of a receptor that mediates protein import into the nucleus, the so-called nuclear localization signal receptor (Goldfarb et al., 1986; Powers and Forbes, 1995) , we found that a conjugate between BSA and nine amino acids from the activation domain of Rev inhibited Rev-mediated export. On the basis of the trans-dominant negative phenotype of Rev mutants in the activation region, Malim et al. (1989b) previously predicted the existence of a trans-acting cellular cofactor involved in Rev-mediated RNA export, and the evidence presented here strongly supports the existence of such a factor. Furthermore, it can be concluded from our competition experiments that the activation domain alone is sufficient to interact with this cofactor. Other Rev domains such as the RNA-binding domain or the multimerization domain are not essential for this interaction. It has previously been shown that multimerization is essential for Rev function (Malim et al., 1989a) . We note that the BSA-R conjugates used here carried roughly 20 peptides. It will be of interest to determine whether conjugates carrying one or a few peptides will be exported. It may be that a high local concentration of Rev NESs will be required for function.
We observed that not only BSA-R but also a BSA conjugate harboring peptides from the HTLV-I Rex activation domain inhibited Rev-mediated export efficiently, supporting earlier suggestions that the activation domains of these proteins are functionally similar (Rimsky et al., 1988) . Our data further suggest that both proteins interact with a common factor that mediates the export of the RNAs of these retroviruses that carry a binding site for the respective protein. In fact, this cellular cofactor might also be responsible for the RNA export of other complex retroviruses that express Rev-like proteins. It will be interesting to determine whether the export of unspliced transcripts of Mason-Pfizer monkey virus, which is the only retroviral case described so far that uses a cellular RNA-binding factor to promote the export of its unspliced transcripts (Bray et al., 1994) , also accesses the same pathway as RREcontaining HIV-1 transcripts.
Probably the most revealing experiment for the action of Rev in RNA export was the demonstration that the acti-vation domain, when conjugated to BSA, was able to direct nuclear export of the conjugate efficiently. Previous work had shown that Rev shuttles rapidly between the nucleus and the cytoplasm, even in the absence of RRE-containing RNA, making it possible that Rev would harbor a signal for nuclear export (Meyer and Malim, 1994; Kaltand et al., 1994; Wolff et al., 1995) . Definition of the Rev activation domain as an NES underlines the bifunctional nature of the Rev protein, with one functional domain being responsible for RNA binding, multimerization, and nuclear import while the other is essential for RNA export.
Importantly, the Rev NES not only facilitates nuclear export in oocytes but also in cultured human somatic (HeLa) cells. Similar export systems that recognize the NES in both organisms and have been conserved in evolution are therefore likely to exist. Interestingly, BSA-R did not localize to nucleoli in HeLa cells. This suggests that the interaction between the NES and the cellular cofactor probably takes place predominantly in the nucleoplasm and that the localization of Rev to nucleoli is not of significance for its export function (Malim et al., 1989a; Kalland et al., 1994) .
Our findings reveal the mechanism of a viral strategy to transport intron-containing pre-mRNA or mRNA molecules from the nucleus to the cytoplasm. Most surprisingly, the limiting factors that are involved in the export of cellular mRNAs appear not to be required for Rev-mediated export. This result is unexpected since the viral RNAs that utilize Rev for their export in HIV-1 infected cells, although unspliced, are in fact mRNAs. On the other hand, BSA-R strongly inhibited U snRNA and 5S rRNA export as well as Rev-mediated RNA export, arguing that there must be a common factor required for the export of these RNA species, It is not possible from the data presented to determine unequivocally whether the difference observed between Rev-mediated U snRNA and 5S rRNA export on the one hand and mRNA, tRNA, and ribosomal subunit export on the other is qualitative or quantitative. Although the model that best fits our data is that the latter group of RNPs do not interact with the same factor as the Rev activation domain during their export, it remains possible that all the RN Ps do interact with one factor but with widely differing affinities, such that the Rev peptide can only compete with some RNPs for this interaction.
Because coinjection of quantities of U snRNAs sufficient to saturate export do not affect 5S rRNA export and because 5S rRNA export could not be saturated at the highest concentrations tested, it was previously concluded that different limiting factors must be required for the export of these two types of RNA (Jarmolowski et al., 1994) . One interpretation of the data presented here in relation to these previous findings is that BSA-R titrates a common factor that acts further downstream in the export process as compared with the factor that is titrated at high U snRNA concentrations, i.e., the cap-binding complex (Jarmolowski et al., 1994; . In other words, the competition experiments can most easily be interpreted to suggest that U snRNAs and 5S rRNA, prior to their export, bind proteins that are functionally equivalent to Rev and interact with the same cellular export factor. Interestingly, TFIIIA, a protein implicated in the export of 5S rRNA (Guddat et al., 1990) , contains a sequence that is highly homologous to the Rev activation domain (Figure 8 ). This sequence may be involved in the proposed interaction. Schmidt-Zachmann et al. (1993) reported that proteins do not absolutely require positively acting export signals for their transport from the nucleus to the cytoplasm, although they noted that export in the absence of such signals exhibited slow kinetics. For the proteins they studied, export from the nucleus was found to be predominantly limited by nuclear retention. Our data show that active and hence signal-mediated nuclear export processes do in fact exist. The rate of BSA-R export is much faster than the export of NES-lacking proteins, implying that the two classes of protein are exported by processes that are mechanistically different. One possible explanation for the observation that Rev requires an active export signal while some proteins do not is that Rev exports RNA molecules that are normally retained in the nucleus. Rev exportpromoting activity therefore has to be dominant over nuclear retention. Proteins whose export rate is determined by the degree of their nuclear retention are unlikely to be able to accomplish this task. The export of different cellular RNA species might in general depend on proteins that harbor positively acting export signals since it has been shown that their export is generally saturable and hence receptor mediated (reviewed by . Positively acting export signals might therefore be located on other possible mediators of RNA export, such as the shuttling protein hnRNP A1 (PiSoI-Roma and Dreyfuss, 1991, 1992) , TFIIIA, ribosomal protein L5 (Guddat et al., 1990) , and the nuclear cap-binding protein complex .
An implication of our results is that similar signals can (and therefore may) be utilized to direct the active export of both proteins and RNPs from the nucleus. It may be that the export of many different macromolecules from the nucleus might therefore be mediated by a small number of signal-receptor systems, but further study will be required to determine whether the situation is, in fact, this simple.
Experimental Procedures
Synthesis of RNA In Vitro
Plasmids pAd46, pAd48, DHFR, U1ASm, 5S, tRNA, and U6 were described previously (Fischer et al. 1994a; Jarmolowski et al., 1994) . Ptasmid DNA was linearized with restriction endonuclease Scal (pAd46), BamHI (pAd48, U1ASm, and U6), Dral (5S), or BstNI (tRNA) and used as template for transcription in vitro with T7 RNA polymerase (Fischer et al., 1994a) . Template DNA was eliminated after transcription by a 15 min incubation at 37°C with 1 i 11 of DNase I (1 U/#.I; Promega, RQ grade). Labeled RNA was extracted with phenoI-CHCI3, precipitated with ethanol, and redissolved in Rev-binding buffer (see below) immediately before use for microinjections. Preparation of in vivo labeled HeLa ribosomes was carried out as described previously (Bataille et al., 1990) .
Microinjection into Oocytes and Analysis of Injected RNA and Protein
Ovaries of X. laevis females were cut into small pieces and incubated for 3-5 hr in modified Barth's solution (Hamm and Mattaj, 1990) containing 0.2% collagenase type II (Sigma). Defolliculated stage V and VI oocytes were collected, stored in small fractions, and used for injection experiments within the following 2 days.
For injection of Rev-RNA complexes, 32P-labeled RRE-RNA (0.5 x 106 to 1 x 106 cpm/#.l; total concentration of 0.7 p.M) was incubated for 30 rain on ice in Rev-binding buffer (1 M NaCt, 20 mM HEPES-KOH [pH 7.9], 2.5 mM MgCI2, 0.5 mM EDTA, 10% glycerol, and 1 mM DTT) in the presence of a 20-fold molar excess of recombinant Rev protein (14 #M) to allow formation of complexes (Fischer et al., 1994a) . 32P-labeled U6 RNA and a 10 mg/ml solution of dextran blue were added to all mixtures to monitor the site of injection; 15 nl of solution was injected per nucleus, and oocytes were then incubated at 20°C. Oocytes were dissected manually, and each fraction was analyzed as described previously (Hamm and Mattaj, 1990) . Injection of iodinated BSA-R and BSA-M conjugates was carried out as described for RNAs. Oocytes were dissected in TNE medium (100 mM NaCI, 1 mM EDTA, and 10 mM Tris-HCI [pH 7.4]). Nuclei were fixed and pelleted in 95% ethanol. The cytoplasms were homogenized in TNE, the insoluble fraction removed by centrifugation, and proteins in the supernatant precipitated with 5 vol of acetone. Precipitated proteins were dissolved in protein sample buffer and fractionated by SDS-PAGE (Laemmli, 1970) . Gels were subsequently fixed in 40% MeOH, 10% acetic acid, dried, and exposed.
Preparation of BSA-Peptide Conjugates
BSA (5 mg) (Boehringer Mannheim) was dissolved in 1 ml of phosphate-buffered saline (PBS) (pH 7.4) and incubated for 1 hr at 20°C with 8 mg of sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohex~.ne-1-carboxylate (sulfo-SMCC) (Pierce Chemical), BSA was subsequently separated from the unreacted sulfo-SMCC by passing the whole mixture over a Sephadex P-10 column (Pharmacia). The purified BSA was then mixed with 5 mg of the desired peptide (BSA-R, BSA-M, or BSA-Rex), dissolved in 1 ml of PBS (pH 6.5), and incubated at 4°C overnight. Conjugation was assessed by SDS-PAG E, and BSA-peptide conjugates were subsequently concentrated to 20 mg/ml in a Minicon 30 concentrator (Amicon). For fluorescent labeling, BSA-R and BSA-M were incubated for 60 min in buffer containing 50% dimethylsulfoxide, 50 mM potassium phosphate buffer (pH 6.8), and a 300-fold molar excess of fluorescein isothiocyanate or N-(resorufin-carbonyl)-N'-(iodoacetyl) piperazine (Boehringer Mannheim). Conjugates were purified and concentrated by P-10 column chromatography and centrifugation in a Centricon C-10 unit (Amicon).
Microinjection into Somatic Cells
HeLa cells were grown to 80% confluence on CELLocate microgrid coverslips (Eppendorf). Microinjection was carried out as described by Fischer et al. (1994b) . The amount of microinjected fluorescent-labeled BSA-R and BSA-M conjugates varied between 5 x 105 and 10 x 102 molecules per cell (100 fi). In competition experiments, a 20-fold excess of BSA-R or BSA-M was coinjected. Cells were incubated in ice-cold 3O/o paraformaldehyde in PBS (pH 7,4) for 15 min. Fixed cells were mounted using Fluorep mounting medium (BioMerieuex), and photographs were taken on a Leitz Aristoplan microscope.
Radioiodination of Proteins
For radioiodination of proteins, a PBS solution containing 50 p.g of either BSA-R or BSA-M, 2 mCi of [~2Sl]Nal, and one lODe-Bead iodination reagent (Pierce) was mixed gently at 20°C for 3 min. Nonincorporated ~51 was subsequently removed by concentration of the reaction mixture in a Centricon C-10 unit (Amicon). The solution injected into oocytes contained approximately 0.25 mg/ml iodinated protein.
